Astragaloside for preventing and treating pulmonary hypertension and use thereof

A technology for pulmonary arterial hypertension and astragaloside IV, applied in the field of astragaloside IV, can solve problems such as pulmonary arterial hypertension that has not been seen with astragaloside IV

Inactive Publication Date: 2018-10-23
SUN YAT SEN UNIV +2
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no application of astragaloside IV in the treatment of pulmonary arterial hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Astragaloside for preventing and treating pulmonary hypertension and use thereof
  • Astragaloside for preventing and treating pulmonary hypertension and use thereof
  • Astragaloside for preventing and treating pulmonary hypertension and use thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0023] Experimental example 1 Effect of astragaloside IV on PE and KCl pre-contracted isolated pulmonary artery vascular ring

[0024] (1) Experimental materials: SPF-grade male Wistar rats were purchased from the Experimental Animal Center of Sun Yat-sen University, injected with phenylephrine hydrochloride (Shanghai Hefeng Pharmaceutical Co., Ltd.), potassium chloride (Tianjin Damao Chemical Reagent Factory) four-chamber organ Bath system SQG4 (Beijing Zhongnuo Far East Technology Co., Ltd.), astragaloside IV (School of Pharmacy, Sun Yat-sen University).

[0025] (2) Experimental method: healthy male Wistar rats with a body weight of 300 ± 20 g were anesthetized with 10% chloral hydrate, and the chest cavity was quickly opened, the heart, lung and esophagus were separated, and the pulmonary artery and its branches were separated, and placed in a pre-passed 95% O 2 +5%CO 2 In the Krebs-Henseleit (K-H) liquid plate with mixed gas, remove the blood stains in the blood vessels ...

experiment example 2

[0027] Experimental Example 2 Effect of astragaloside IV on monocrotaline-induced pulmonary hypertension model rats

[0028] The monocrotaline-induced pulmonary hypertension model in rats was established by Yuzo Hayashi in 1967. It is currently widely used in the evaluation of pulmonary circulation hemodynamic changes and drug efficacy. It is a relatively feasible and ideal pulmonary hypertension model.

[0029] (1) Experimental materials

[0030] Experimental animals: 48 SPF grade Wistar rats, 10 weeks old, weighing 200-230g, male, purchased from the Experimental Animal Center of Sun Yat-sen University (permit number: SYXK (Guangdong) 2011-0029), ambient temperature: 20-25 ℃, humidity 50-70%, free to eat and drink.

[0031] Monocrotaline (Guangzhou Qiyun Biotechnology Co., Ltd.), rat NO kit (Nanjing Jiancheng Institute of Bioengineering), rat ET-1 ELISA kit (Wuhan Huamei), astragaloside IV (School of Pharmacy, Sun Yat-sen University).

[0032] (2) Experimental method

[0033...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to astragaloside for preventing and treating pulmonary hypertension and a use thereof. The astragaloside (I) is an astragaloside substance extracted from plant radix astragali. The modern pharmacological research result shows that the astragaloside mainly has effects of immune regulation, ischemia protection, cardioprotection, inflammation diminishing, viral resistance and tumor resistance, is used for treating viral myocarditis, cardiac insufficiency and hepatitis caused by dampness stagnancy due to spleen deficiency in clinic, can be used for preventing and / or treatingpulmonary arterial hypertension, can be used for preparation of drugs for reducing pulmonary arterial hypertension-caused rat ventriculus dexter hypertrophy index and mean pulmonary artery pressure, can be used for preparation of drugs for improving plasma NO content and reducing plasma ET-1 content and can be used for preparation of drugs for affecting rat pulmonary arterial hypertension tissue pathological structures.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to astragalosides IV for preventing and treating pulmonary hypertension and applications thereof. Background technique [0002] Pulmonary arterial hypertension (PAH) is a pathophysiological syndrome characterized by persistent increase in pulmonary vascular resistance. Its pathogenesis is complex and has not yet been clarified. The clinical manifestations are increased right ventricular afterload, decreased activity tolerance, and even death due to right ventricular failure. [0003] The vessel wall is generally composed of an adventitia containing collagen fibers and elastic fibers, a media containing smooth muscle cells, and an intima containing endothelial cells. Pulmonary vascular remodeling is one of the important pathophysiological characteristics of pulmonary arterial hypertension. It is manifested by thickening of the three layers of the pulmonary artery wall at all level...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/12A61P37/02A61P9/10A61P29/00A61P31/12A61P35/00A61P9/00A61P31/14
CPCA61K31/7048A61P9/00A61P9/10A61P9/12A61P29/00A61P31/12A61P31/14A61P35/00A61P37/02
Inventor 刘培庆由天辉陈健文王权蔡梦婷
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap